Transcript
Paliperidone palmitate was the second one that became available. It does not require much oral supplementation. You only have to give it for a two-day period of either risperidone or paliperidone ER tablet just prior to starting the IM to demonstrate tolerability.
And the real advantage to paliperidone palmitate in being able to get it going right away, the usual process is to start with a 234 mg IM injection and then a week later, you can give the 156 mg dose and then continue, for the average patient, 156 every four weeks. So this gets them up to therapeutic concentration rapidly without the need for the oral supplementation. Subsequent injections as I said would be every four weeks for the Sustenna version. But there’s also now a three-month formulation Invega Trinza which may be started after four months on the monthly paliperidone palmitate. And the usual dose of that is 546 mg every three months.
References
- Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies . Br J Psychiatry Suppl 2009;52:S20Y8.
- Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia . Br J Psychiatry 2001;179:290Y9
- Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review . Br J Psychiatry Suppl 2009;52:S13Y9
- Boaz TL, Constantine RJ, Robst J, Becker MA, Howe AM. Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population . J Clin Psychiatry 2011;72:1079Y85
- Citrome L. Paliperidone palmitate: review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication . Int J Clin Pract 2010;64:216Y39.
- Bishara D. Once-monthly paliperidone injection for the treatment of schizophrenia . Neuropsychiatr Dis Treat 2010;6:561Y72.
- Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia . Am J Psychiatry 2010;167:181Y9
- Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, Corya SA. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases . BMC Psychiatry 2010;10:43.
- Abilify Maintena US ®. [Prescribing information] Otsuka America Pharmaceutical, Inc., Rockville, MD
- Aristada® [Prescribing information]. Waltham, MA: Alkermes, Inc.; 2017
